<DOC>
	<DOCNO>NCT01815021</DOCNO>
	<brief_summary>Primary objective : Phase I Proof concept : treatment small dos elemental calcium ACC compare CCS maintain target serum calcium ( correct albumin ) value ( 7.0-10.0 mg/dL ) . Phase II To test hypothesis treatment small dos elemental calcium ACC compare CCS maintain target serum calcium ( correct albumin ) value ( 7.0-10.0 mg/dL ) . Secondary objective : Phase I - ACC dose selection - confirm conversion factor ACC CCS - To determine effect food ACC absorption Phase II - To test hypothesis treatment small dos elemental calcium ACC compare CCS cause increase hypercalciuria patient hypoparathyroidism - To test hypothesis small dos elemental calcium ACC reduce side effect relate high calcium consumption . Amorphical strong basis believe ACC product well absorb compare commercially available CCS product therefore , maintain desirable target albumin correct calcium value serum ( CA ) small dos elemental calcium ACC . As result , burden take high dos calcium supplementation along side effect standard therapy ( gastrointestinal discomfort hypercalciuria ) reduce . Testing serum CA urine calcium value subject hypoparathyroidism may provide straightforward method test hypothesis . The study design conduct extra precaution order avoid disturb fragile balance CA level serum calcium level urine . The crossover design phase II study allow accurate reliable comparison result attributable specific treatment within individual . In addition , subject continue consume routine medication throughout trial . The subject control arm consume routine calcium supplement dose thus , treat standard care .</brief_summary>
	<brief_title>A Study Comparing Amorphous Calcium Carbonate ( ACC ) Versus Crystalline Calcium CCS ) Hypoparathyroidism Patients</brief_title>
	<detailed_description>Eligible subject treat follow : Phase I Ten ( 10 ) subject previously diagnose chronically treated primary hypoparathyroidism enrol . The daily CCS intake gradually replace reduced amount elemental calcium ACC . Five ( 5 ) subject consume ACC meal five ( 5 ) subject consume ACC meal . The safety efficacy treatment closely monitor throughout phase . The absorption ACC evaluate use weekly serum calcium correct albumin ( CA ) value test . Excretion calcium urine test screening end phase I. I-Day -21 ( +/-17 ) Screening : Subjects diagnose primary hypoparathyroidism ( see section 4.1 definition ) , treat calcium vitamin D supplementation least 1 year prior begin study without major renal hepatic disease , invited Clinical Research Center . At clinic , subject interview , medical history current medication document sign inform consent form ( ICF ) . Subjects refer perform blood test serum calcium , P , creatinine albumin level . Calculation albumin correct calcium ( CA ) perform . Subjects instruct perform 24 hour urine collection Ca , P creatinine . Subjects ask fill food medication diary 3 consecutive day evaluate daily dietary calcium intake . Women childbearing age undergo urine pregnancy test . Eligible subject , comply inclusion criterion none exclusion criterion enrol study . Subjects inform phone site whether eligible enter study . I-Day 0 : Eligible subject arrive Clinical Research Center ask change medical condition since last visit . Blood test perform define serum calcium , P albumin baseline value . Calculation CA baseline perform . Subjects receive pack ACC tablet , tablet contain 50 , 100 200 mg elemental calcium ( accord daily total amount calcium supplementation , 14 day supply + 5 spare tablet ) . The replacement CCS ACC calculate accord follow formula : NTDC = ITDC - [ 0.1×ITDC ( mg CCS ) ] + [ 0.05×ITDC ( mg ACC ) ] *ITDC - Initial total daily calcium intake ( mg ) **NTDC - New total daily calcium intake ( mg ) 10 % ( mg ) initial total daily intake elemental calcium replace 5 % elemental calcium ACC ( mg , calculate initial total daily intake ) . The daily intake vitamin D remain . The calculation number tablet per day perform specifically subject ( accord daily dosage calcium supplementation ) doctor . Subjects instruct take XXX ACC tablet day , accord individual calculated NTDC : 1 . Five subject instruct take XXX tablet morning meal , XXX midday meal XXX evening meal . 2 . Five subject instruct take XXX tablet morning meal , XXX midday meal XXX evening meal . Subjects instruct continue routine medication consumption trial . I-Day 3 ( ±1 ) : Subjects arrive Clinical Research Center serum calcium , P albumin level test . Calculation CA perform exclude hypocalcaemia ( Ca &lt; 7.0 mg/dL ) . If CA value within desire target range ( 7.0-10.0 mg/dl ) , subject continue take calcium dos instruct I-day 0 . If CA value 7.0 mg/dl 10.0 mg/dl , change calcium intake make , accord doctor 's decision . I-Day 7 ( ±1 ) : Subjects arrive Clinical Research Center serum calcium , P albumin level test . Calculation CA perform : 1 . Conversion factor 0.5 : If CA = baseline , 20 % ( mg , calculate initial total daily intake ) elemental calcium replace 10 % elemental calcium ACC ( mg , calculate initial total daily intake ) . NTDC = ITDC - [ 0.2×ITDC ( mg CCS ) ] + [ 0.1×ITDC ( mg ACC ) ] 2 . Conversion factor 0.75 : If CA &lt; baseline , 10 % ( mg , calculate initial total daily intake ) elemental calcium replace 7.5 % elemental calcium ACC ( mg , calculate initial total daily intake ) . NTDC = ITDC - [ 0.1×ITDC ( mg CCS ) ] + [ 0.075×ITDC ( mg ACC ) ] CA &lt; 7.00 mg/dl enforce end treatment . 3 . Conversion factor 0.25 : If CA &gt; baseline , 10 % ( mg , calculate initial total daily intake ) elemental calcium replace 2.5 % elemental calcium ACC ( mg , calculate initial total daily intake ) . NTDC = ITDC - [ 0.1×ITDC ( mg CCS ) ] + [ 0.025×ITDC ( mg ACC ) ] Subjects ask side effect AEs may occur change concomitant medication since last visit . Subjects ask symptom sign related change serum calcium level ( tetany , facial grimacing , paresthesia , muscle ache , arrhythmia , depression ) . Subjects receive instruction regard new dos ACC remind take XXX tablet day ( accord individual calculate NTDC ) , XXX morning , XXX midday XXX evening , meal ( base initial assignment ) . Subjects remind continue routine medication consumption trial . I-Day 10 ( ±1 ) : Subjects arrive Clinical Research Center serum calcium , P albumin level test . Calculation CA perform exclude hypocalcaemia ( Ca &lt; 7.0 mg/dL ) . If CA level within desire target range ( 7.0-10.0 mg/dl ) , subject continue take calcium dos instruct I-day 7 . If CA level 7.0 mg/dl 10.0 mg/dl , change calcium intake make , accord doctor 's decision . I-Day 14 ( ±1 ) : Subjects arrive Clinical Research Center serum calcium , P albumin level test . Calculation CA perform exclude hypocalcaemia ( Ca &lt; 7.0 mg/dL ) . If none conversion formula ( a-c , I-Day 7 ) result serum calcium value within desire target range ( 7.0-10.0 mg/dL ) , study terminate . Subjects ask side effect AEs may occur change concomitant medication since last visit . Subjects ask symptom sign related change serum calcium level ( tetany , facial grimacing , paresthesia , muscle ache , arrhythmia , depression ) . 50 % initial daily supplementation CCS replace ACC base conversion factor find I-day 7 ( formulas a-c ) : 1 . Conversion factor 0.5 : 50 % ( mg , calculate initial total daily intake ) elemental calcium replace 25 % elemental calcium ACC ( mg , calculate initial total daily intake ) . NTDC = ITDC - [ 0.5×ITDC ( mg CCS ) ] + [ 0.25×ITDC ( mg ACC ) ] 2 . Conversion factor 0.75 : 50 % ( mg , calculate initial total daily intake ) elemental calcium replace 37.5 % elemental calcium ACC ( mg , calculate initial total daily intake ) . NTDC = ITDC - [ 0.5×ITDC ( mg CCS ) ] + [ 0.375×ITDC ( mg ACC ) ] 3 . Conversion factor 0.25 : 50 % ( mg , calculate initial total daily intake ) elemental calcium replace 12.5 % elemental calcium ACC ( mg , calculate initial total daily intake ) . NTDC = ITDC - [ 0.5×ITDC ( mg CCS ) ] + [ 0.125×ITDC ( mg ACC ) ] Subjects receive pack ACC tablet , tablet contain 50 , 100 200 mg elemental calcium ( accord individual calculate NTDC , 14 day supply + 5 spare tablet ) . Subjects receive instruction regard new dos ACC remind take XXX capsule day , XXX morning , XXX midday XXX evening , meal ( base initial assignment ) . Subjects remind continue routine medication consumption trial . I-Day 21 ( ±1 ) : Subjects arrive Clinical Research Center serum calcium , P albumin level test . Calculation CA perform exclude hypocalcaemia ( Ca &lt; 7.0 mg/dL ) . Subjects ask side effect AEs may occur change concomitant medication since last visit . Subjects ask symptom sign related change serum calcium level ( tetany , facial grimacing , paresthesia , muscle ache , arrhythmia , depression ) . If CA level 7.0 mg/dl , 10.0 mg/dl , subject exclude study ( base doctor 's decision ) . If CA level within desire target range ( 7.0-10.0 mg/dL ) , complete replacement daily supplementation CCS ACC perform , base conversion factor find I-day 7 ( formulas a-c ) : 1 . Conversion factor 0.5 : 100 % ( mg ) elemental calcium initial total daily intake replace 50 % elemental calcium ACC ( mg , calculate initial total daily intake ) . NTDC = ITDC - [ ITDC ( mg CCS ) ] + [ 0.5×ITDC ( mg ACC ) ] 2 . Conversion factor 0.75 : 100 % ( mg ) elemental calcium initial total daily intake replace 75 % elemental calcium ACC ( mg , calculate initial total daily intake ) . NTDC = ITDC - [ ITDC ( mg CCS ) ] + [ 0 . 75×ITDC ( mg ACC ) ] 3 . Conversion factor 0.25 : 100 % ( mg ) elemental calcium initial total daily intake replace 25 % elemental calcium ACC ( mg , calculate initial total daily intake ) . NTDC = ITDC - [ ITDC ( mg CCS ) ] + [ 0.25×ITDC ( mg ACC ) ] Subjects receive instruction regard new dos ACC remind take XXX tablet day , XXX morning , XXX midday XXX evening , meal ( base initial assignment ) . Subjects remind continue routine medication consumption trial . Subjects receive container perform 24 hour urine collection prior next scheduled visit . I-Day 27 ( ±1 ) phone : Subjects remind perform 24 hour urine collection . I-Day 28 ( ±1 ) - Termination phase I : Subjects arrive Clinical Research Center serum calcium , P albumin level test . Calculation CA perform . Subjects provide container 24 hour urine collection Ca , P creatinine test calciuria . Subjects ask side effect AEs may occur change concomitant medication since last visit . Subjects ask symptom sign related change serum calcium level ( tetany , facial grimacing , paresthesia , muscle ache , arrhythmia , depression ) . Phase I result examine decide whether embark crossover portion study plan Phase II . Phase I data summarize , show subject , arm overall relationship CA level amount ACC replacement CCS receive . Phase II Ten ( 10 ) subject previously diagnose chronically treated primary hypoparathyroidism enrol . Subjects participate phase I offer participate phase II well . If need , new subject enrol . The subject randomly assign one follow treatment 6 week : 1 . Standard care ( CCS ) - The elemental calcium dosage use routinely prior study . 2 . ACC - The establish dosage elemental calcium ACC ( base conversion factor fed/fasted condition find phase I study ) . The two formulation administer regular daily dosage vitamin D ( 1-alfa D3 ) . At end treatment , group receive alternative formulation another 6 week . The superior absorption ACC evaluate use weekly blood test calculate serum CA value . Excretion calcium urine test screening end treatment . II-Day -21 ( +/-17 ) Screening : Subjects diagnose primary hypoparathyroidism ( see section 4.1 definition ) , receive calcium vitamin D supplementation least 1 year prior begin study without major renal hepatic disease , invited Clinical Research Center . At clinic , subject interview , medical history current medication document sign inform consent form ( ICF ) . Subjects refer perform blood test Calcium , P albumin level . Calculation CA perform . Subjects instruct perform 24 hour urine collection Ca , P creatinine level . Subjects ask fill food medication diary 3 consecutive day evaluate daily dietary calcium intake . Women childbearing age undergo urine pregnancy test . Eligible subject , comply inclusion criterion none exclusion criterion enrol study . Subjects inform phone site whether eligible enter study . II-Day 0 : Eligible subject arrive Clinical Research Center ask change medical condition since last visit . Blood test perform define serum calcium , P albumin baseline value . CA value calculate baseline . Subjects randomly assign one follow treatment : 1 . Standard-of-care ( CCS ) - The elemental calcium dosage use routinely prior study . 2 . ACC - The establish dosage elemental calcium ACC ( base conversion factor fed/fasted condition find phase I study ) . Subjects assign ACC treatment arm , receive pack ACC tablet , tablet contain 200 mg elemental calcium ( 35 day supply + 5 spare tablet ) . Subjects assign CCS treatment arm continue take routine calcium supplementation . The exact dosage calcium supplementation determine subject accord known medical history . Subjects instruct continue routine medication consumption trial . II-Day 3 ( ±1 ) : Subjects arrive Clinical Research Center serum calcium , P albumin level test . Calculation CA perform exclude hypocalcaemia ( Ca &lt; 7.0 mg/dL ) . If CA value within desire target range ( 7.0-10.0 mg/dl ) , subject continue take calcium dos instruct II-day 0 . If CA level 7.0 mg/dL 10.0 mg/dL , change calcium intake make , accord doctor 's decision II-Day 7 ( ±1 ) : Subjects arrive Clinical Research Center serum calcium , P albumin level test . Calculation CA perform . Subjects ask side effect AEs may occur change concomitant medication since last visit . Subjects ask symptom sign related change serum calcium level ( tetany , facial grimacing , paresthesia , muscle ache , arrhythmia , depression ) . Adjustments ACC CCS intake perform necessary . Subjects remind take calcium supplementation accord assignment instruction . Subjects remind continue routine medication consumption trial . II-Day 10 ( ±1 ) : Subjects arrive Clinical Research Center serum calcium , P albumin level test . Calculation CA perform exclude hypocalcaemia ( Ca &lt; 7.0 mg/dL ) . If CA level within desire target range ( 7.0-10.0 mg/dl ) , subject continue take calcium dos instruct II-day 7 . If CA level 7.0 mg/dL , 10.0 mg/dL , change calcium intake make , accord doctor 's decision II-Day 14 ( ±1 ) : Subjects arrive Clinical Research Center serum calcium , P albumin level test . Calculation CA perform . Subjects ask side effect AEs may occur change concomitant medication since last visit . Subjects ask symptom sign related change serum calcium level ( tetany , facial grimacing , paresthesia , muscle ache , arrhythmia , depression ) . Subjects reminded take calcium supplementation accord assignment instruction . Subjects remind continue routine medication consumption trial . II-Day 21 ( ±1 ) : Subjects arrive Clinical Research Center serum calcium , P albumin test . Calculation CA perform . Subjects ask side effect AEs may occur change concomitant medication since last visit . Subjects ask symptom sign related change serum calcium level ( tetany , facial grimacing , paresthesia , muscle ache , arrhythmia , depression ) . Subjects reminded take calcium supplementation accord instruction . Subjects remind continue routine medication consumption trial . Subjects receive container perform 24 hour urine collection prior next scheduled visit . II-Day 34 ( ±1 ) phone : Subjects remind perform 24 hour urine collection . II-Day 35 ( ±1 ) : Subjects arrive Clinical Research Center serum calcium , P albumin level test . Calculation CA perform . Subjects provide container 24 hour urine collection Ca , P creatinine test calciuria . Subjects ask side effect AEs may occur change concomitant medication since last visit . Subjects ask symptom sign related change serum calcium level ( tetany , facial grimacing , paresthesia , muscle ache , arrhythmia , depression ) . Subjects previously assign CCS treatment arm receive pack ACC tablet , tablet contain 200 mg elemental calcium ( 35 day supply + 5 spare tablet ) . Subjects previously assign ACC treatment arm , instructed resume regular CCS supplementation . The exact dosage calcium supplementation subject determine known medical history . Subjects remind continue routine medication consumption trial . II-Day 38 ( ±1 ) : Subjects arrive Clinical Research Center serum calcium , P albumin level test . Calculation CA perform exclude hypocalcaemia ( Ca &lt; 7.0 mg/dL ) . If CA level within desire target range ( 7.0-10.0 mg/dl ) , subject continue take calcium dos instruct II-day 35 . If CA level 7.0 mg/dl 10.0 mg/dl , change calcium intake make , accord doctor 's decision II-Day 42 ( ±1 ) : Subjects arrive Clinical Research Center serum calcium , P albumin level test . Calculation CA perform . Subjects ask side effect AEs may occur change concomitant medication since last visit . Subjects ask symptom sign related change serum calcium level ( tetany , facial grimacing , paresthesia , muscle ache , arrhythmia , depression ) . Adjustments ACC CCS intake perform necessary . Subjects remind take calcium supplementation accord assignment instruction . Subjects remind continue routine medication consumption trial . II-Day 45 ( ±1 ) : Subjects arrive Clinical Research Center serum calcium , P albumin level test . Calculation CA perform exclude hypocalcaemia ( Ca &lt; 7.0 mg/dL ) . If CA level within desire target range ( 7.0-10.0 mg/dl ) , subject continue take calcium dos instruct II-day 42 . If CA level 7.0 mg/dl 10.0 mg/dl , change calcium intake make , accord doctor 's decision II-Day 49 ( ±1 ) : Subjects arrive Clinical Research Center serum calcium , P albumin level test . Calculation CA perform . Subjects ask side effect AEs may occur change concomitant medication since last visit . Subjects ask symptom sign related change serum calcium level ( tetany , facial grimacing , paresthesia , muscle ache , arrhythmia , depression ) . Subjects reminded take calcium supplementation accord assignment instruction . Subjects remind continue routine medication consumption trial . II-Day 56 ( ±1 ) : Subjects arrive Clinical Research Center serum calcium , P albumin level test . Calculation CA perform . Subjects ask side effect AEs may occur change concomitant medication since last visit . Subjects ask symptom sign related change serum calcium level ( tetany , facial grimacing , paresthesia , muscle ache , arrhythmia , depression ) . Subjects reminded take calcium supplementation accord assignment instruction . Subjects remind continue routine medication consumption trial . Subjects receive container perform 24 hour urine collection prior next scheduled visit . II-Day 69 ( ±1 ) phone : Subjects remind perform 24 hour urine collection . II-Day 70 ( ±1 ) - Termination phase II : Subjects arrive Clinical Research Center serum calcium , P albumin level test . Calculation CA perform . Subjects provide container 24 hour urine collection Ca , P creatinine test calciuria . Subjects ask side effect AEs may occur change concomitant medication since last visit . Subjects ask symptom sign related change serum calcium level ( tetany , facial grimacing , paresthesia , muscle ache , arrhythmia , depression ) .</detailed_description>
	<mesh_term>Hypoparathyroidism</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Primary Hypoparathyroidism low level intact PTH hypocalcemia diagnosis . Subjects receive calcium vitamin D supplementation least 1 year prior begin study . Subjects able adhere visit schedule protocol requirement available complete study . Subjects provide write informed consent participate study . Age : 1880 , inclusive . Calcium ( albumin correct ) serum value 7.0 mg/dL 10.0 mg/dL Any known disease affect absorption gastrointestinal tract : Inflammatory bowel disease ( e.g. , Crohn 's disease , ulcerative colitis ) Chronic diarrhea Subjects neuropsychiatric disease . Subjects impaired renal function ( glomerular filtration rate , ≤40 mL/min ) Subjects severe chronic disease require longterm therapy . Impaired liver function ( Liver enzymes &gt; x3 upper limit normal ) . Subjects history presence kidney stone Recurrent urinary tract infection Subjects take drug might affect calcium level : Fusid Anticonvulsants Carbonic anhydrase Adrenocorticosteroids Subjects noncooperative unwilling sign consent form . Pregnant breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>